Novavax sees weak Covid vaccine sales
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi (SASY.PA), opens new tab.
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine
Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its Covid-19 and influenza combination vaccine (CIC) and standalone influenza vaccines after a month-long clinical hold. The FDA initially ...
Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter ...
Novavax Inc.’s stock fell 4% Tuesday after the company cut its full-year guidance, offsetting a narrower-than-expected ...
Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu ...
Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...
Novavax's COVID-19 vaccine continues to be its only commercial product and currently has about 2%-3% market share, ...
The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 ...
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
Hosted on MSN1d
Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call TranscriptThis strategy has already resulted in the Sanofi partnership we announced this year, which has enabled us to transition away ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback